Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2009

01-12-2009 | Original Article

A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer

Authors: Noboru Yamamoto, Tomohide Tamura, Takayasu Kurata, Nobuyuki Yamamoto, Ikuo Sekine, Hideo Kunitoh, Yuichiro Ohe, Nagahiro Saijo

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2009

Login to get access

Abstract

Purpose

Nedaplatin is a second-generation platinum showing favorable activity against non-small cell lung cancer (NSCLC). Dose-limiting toxicity (DLT) is thrombocytopenia, predicted by creatinine clearance (Ccr). This study was conducted to determine the recommended dose, and evaluate the toxicities, pharmacokinetics and efficacy for elderly NSCLC patients.

Methods

Patients ≥70 years were stratified into two groups based on renal functions: Group A, Ccr ≥ 60 and Group B, 40 ≤ Ccr < 60. The initial doses were 80 and 60 mg/m2 in Groups A and B, respectively. The doses were escalated in 20-mg/m2 increments to 100 mg/m2 until DLT.

Results

Chemotherapy-naïve 39 elderly patients (Group A/Group B: 22/17) received a total of 83 cycles. Major toxicities were hematological. In Group A, one of the 15 patients at 100 mg/m2 experienced DLT (neutropenia) and the recommended dose was determined at 100 mg/m2. In Group B, three of the five patients had DLTs (leukopenia, neutropenia, thrombocytopenia and febrile neutropenia) at 100 mg/m2, and the recommended dose was determined at 80 mg/m2. The percentage decreases of neutrophil were well correlated with total and free-Pt AUCs. Partial responses were observed in 13 (33%) of the 39 patients, and 12 of the 13 patients who responded had a squamous cell carcinoma.

Conclusions

Nedaplatin was administered simply and feasibly by stratifying renal function and exerted favorable antitumor activity for elderly patients with NSCLC, especially on squamous cell carcinoma.
Literature
1.
Kaneko S, Ishikawa KB, Yoshimi I et al (2003) Projection of lung cancer mortality in Japan. Cancer Sci 94:919–923PubMedCrossRef
2.
Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef
3.
Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323PubMedCrossRef
4.
Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261PubMedCrossRef
5.
Oshita F, Kurata T, Kasai T et al (1995) Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 86:1198–1202PubMed
6.
Yamamoto N, Tamura T, Maeda M et al (1995) The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function. Cancer Chemother Pharmacol 36:102–106PubMedCrossRef
7.
Kanzawa F, Matsushima Y, Nakano H et al (1988) Antitumor activity of a new platinum compound (glycolate-O,O′) diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Anticancer Res 8:323–327PubMed
8.
Suzumura Y, Kato T, Ueda R et al (1989) Effect of treatment schedule on antitumor activity of glycolate-0, 0′-diammineplatinum(II), a new platinum derivative: comparison with cis-diamminedichloroplatinum(II). Anticancer Res 9:1083–1088PubMed
9.
Hida S, Okada K, Yoshida O (1990) Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts. Jpn J Cancer Res 81:425–430PubMed
10.
Furuse K, Fukuoka M, Kurita Y et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho 19:879–884PubMed
11.
Sasaki Y, Fukuda M, Morita M et al (1990) Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O′)-diammine platinum (II) (NSC 375101D). Jpn J Cancer Res 81:196–200PubMed
12.
LeRoy AF, Wehling ML, Sponseller HL et al (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184–191PubMedCrossRef
13.
Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165–175PubMedCrossRef
14.
Sasaki Y, Tamura T, Eguchi K et al (1989) Pharmacokinetics of (glycolate-O,O′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246PubMedCrossRef
15.
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer: The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91:66–72CrossRef
16.
Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372PubMedCrossRef
17.
Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG 9904). J Clin Oncol 24:3657–3663PubMedCrossRef
18.
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed
19.
Kato H, Fukuchi M, Manda R et al (2003) Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Anticancer Res 23:3493–3498PubMed
20.
Kodaira T, Fuwa N, Tachibana H et al (2006) Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. Anticancer Res 26:2265–2268PubMed
21.
Yoshioka T, Sakayori M, Kato S et al (2006) Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation. Int J Clin Oncol 11:454–460PubMedCrossRef
22.
Kanai M, Matsumoto S, Nishimura T et al (2007) Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer. Int J Clin Oncol 12:224–227PubMedCrossRef
Metadata
Title
A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer
Authors
Noboru Yamamoto
Tomohide Tamura
Takayasu Kurata
Nobuyuki Yamamoto
Ikuo Sekine
Hideo Kunitoh
Yuichiro Ohe
Nagahiro Saijo
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1006-9

Other articles of this Issue 1/2009

Cancer Chemotherapy and Pharmacology 1/2009 Go to the issue

Original Article

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate

Original Article

Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

Original Article

Biological reactive intermediates that mediate dacarbazine cytotoxicity

Original Article

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

Original Article

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies

Original Article

PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits